Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 43.4933
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2631
- MktCap 723075181200.0
- FreeCF/Share 0.5421
- PFCF 1484.1445
- PE 61.7359
- Debt/Assets 0.4309
- DivYield 0.0073
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 …
Read More
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Read More
Lilly set for strong quarter after Novo profit warning
Published: July 29, 2025 by: Reuters
Sentiment: Positive
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.
Read More
The Big 3: OKTA, LLY, ADSK
Published: July 25, 2025 by: Schwab Network
Sentiment: Positive
@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technical breakout," and Autodesk's (ADSK) path to reclaim its 52-week high.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Published: July 24, 2025 by: Business Wire
Sentiment: Neutral
BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to $856 million. The updated release reads: GATE BIOSCIENCE ENTERS INTO A COLLABORATION AND LICENSE AGREE.
Read More
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
Published: July 24, 2025 by: Benzinga
Sentiment: Positive
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials
Read More
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
Published: July 24, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Read More
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.
Read More
Calls of the Day: Eli Lilly and Materion
Published: July 18, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Read More
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
CVS drops Lilly's Zepbound
Published: July 01, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles reports on news regarding CVS.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Read More
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Read More
Lilly declares third-quarter 2025 dividend
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.
Read More
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Published: June 22, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used …
Read More
Final Trade: LLY, SHEL, USO, WMT
Published: June 20, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with the Fast Money traders.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000